Tyrosine hydroxylase gene: another piece of the genetic puzzle of Parkinson's disease
- PMID: 22583432
- PMCID: PMC3973181
- DOI: 10.2174/187152712800792866
Tyrosine hydroxylase gene: another piece of the genetic puzzle of Parkinson's disease
Abstract
The tyrosine hydroxylase (TH) gene encodes a monoxygenase that catalyzes the rate limiting step in dopamine biosynthesis. A hallmark of Parkinson's disease (PD) is the loss of dopaminergic neurons in the substantia nigra. Consistent with the essential role of TH in dopamine homeostasis, missense mutations in both alleles of TH have been associated with severe Parkinsonism-related phenotypes including infantile Parkinsonism. It has been speculated for a long time that genetic variants in the TH gene modify adult-onset PD susceptibility but the answer has not been clear. Genetic variants (both sequence variations and structural variations) can be classified into three categories based on their relative frequency in population: common variants (polymorphisms), rare variants and mutations. Each of these factors has a different mode in influencing the genetic risk and often requires different approaches to decipher their contributions to the disease. In the past few years, the revolutionary advances in genomic technology have allowed systematic evaluations of these genetic variants in PD, such as the genome-wide association study (GWAS, to survey common variants), copy number variation analysis (to detect structural variations), and massive parallel next generation sequencing (to detect rare variants and mutations). In this review, we have summarized the latest evidence on TH genetic variants in PD, including our ongoing effort of using whole exome sequencing to search for rare variants in PD patients.
Conflict of interest statement
Declared none.
Figures

Similar articles
-
Human tyrosine hydroxylase in Parkinson's disease and in related disorders.J Neural Transm (Vienna). 2019 Apr;126(4):397-409. doi: 10.1007/s00702-018-1903-3. Epub 2018 Jul 11. J Neural Transm (Vienna). 2019. PMID: 29995172 Review.
-
Overview of tyrosine hydroxylase in Parkinson's disease.CNS Neurol Disord Drug Targets. 2012 Jun 1;11(4):350-8. doi: 10.2174/187152712800792901. CNS Neurol Disord Drug Targets. 2012. PMID: 22483316 Review.
-
GCH1 Deficiency Activates Brain Innate Immune Response and Impairs Tyrosine Hydroxylase Homeostasis.J Neurosci. 2022 Jan 26;42(4):702-716. doi: 10.1523/JNEUROSCI.0653-21.2021. Epub 2021 Dec 7. J Neurosci. 2022. PMID: 34876467 Free PMC article.
-
A rare novel deletion of the tyrosine hydroxylase gene in Parkinson disease.Hum Mutat. 2010 Oct;31(10):E1767-71. doi: 10.1002/humu.21351. Hum Mutat. 2010. PMID: 20809526 Free PMC article.
-
Effect of siRNA-induced silencing of cellular prion protein on tyrosine hydroxylase expression in the substantia nigra of a rat model of Parkinson's disease.Genet Mol Res. 2016 May 9;15(2). doi: 10.4238/gmr.15027406. Genet Mol Res. 2016. PMID: 27173342
Cited by
-
Complex molecular regulation of tyrosine hydroxylase.J Neural Transm (Vienna). 2014 Dec;121(12):1451-81. doi: 10.1007/s00702-014-1238-7. Epub 2014 May 28. J Neural Transm (Vienna). 2014. PMID: 24866693 Review.
-
Contribution of dopaminergic polymorphisms to levodopa treatment response and drug concentration in Chinese patients with Parkinson's disease.Clin Park Relat Disord. 2025 Apr 20;12:100333. doi: 10.1016/j.prdoa.2025.100333. eCollection 2025. Clin Park Relat Disord. 2025. PMID: 40671874 Free PMC article.
-
Human tyrosine hydroxylase in Parkinson's disease and in related disorders.J Neural Transm (Vienna). 2019 Apr;126(4):397-409. doi: 10.1007/s00702-018-1903-3. Epub 2018 Jul 11. J Neural Transm (Vienna). 2019. PMID: 29995172 Review.
-
Copy number variability in Parkinson's disease: assembling the puzzle through a systems biology approach.Hum Genet. 2017 Jan;136(1):13-37. doi: 10.1007/s00439-016-1749-4. Epub 2016 Nov 28. Hum Genet. 2017. PMID: 27896429 Free PMC article. Review.
-
Associations between catecholaminergic, GABAergic, and serotonergic genes and self-reported attentional function in oncology patients and their family caregivers.Eur J Oncol Nurs. 2015 Jun;19(3):251-9. doi: 10.1016/j.ejon.2014.11.004. Epub 2014 Dec 15. Eur J Oncol Nurs. 2015. PMID: 25524657 Free PMC article.
References
-
- Fahn S. Description of Parkinson’s disease as a clinical syndrome. Ann NY Acad Sci. 2003;991:1–14. - PubMed
-
- Hancock DB, Martin ER, Fujiwara K, Stacy MA, Scott BL, Stajich JM, Jewett R, Li YJ, Hauser MA, Vance JM, Scott WK. NOS2A and the modulating effect of cigarette smoking in Parkinson’s disease. Ann Neurol. 2006;60:366–373. - PubMed
-
- Li Y, Oliveira SA, Xu P, Martin ER, Stenger JE, Scherzer CA, Hulette C, Scott WK, Small GW, Nance MA, Watts RL, Hubble JP, Koller WC, Pahwa R, Stern MB, Hiner BC, Jankovic J, Goetz CG, Mastaglia F, Middleton LT, Roses AD, Saunders AM, Welsh-Bohmer KA, Schmechel DE, Gullans SR, Haines JL, Gilbert JR, Vance JM, Pericak-Vance MA. Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet. 2003;12:3259–3267. - PubMed
-
- Oliveira S, Li Y, XJQ, Zuchner S, Noureddine MA, Hauser MA, TS, SE, Pericak-Vance MA, JMV Novel genes associated with risk and age-at-onset in parkinson disease identified through iterative association mapping. American Society of Human Genetics; Toronto, Canada. October 26–30: 2004; 2005.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous